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Abstract
Background: While both preclinical and clinical studies suggest that the frequency of growing skeletal metastases
is elevated in individuals with higher bone turnover, it is unclear whether this is a result of increased numbers of
tumour cells arriving in active sites or of higher numbers of tumour cells being induced to divide by the bone
micro-environment. Here we have investigated how the differences in bone turnover affect seeding of tumour cells
and/or development of overt osteolytic bone metastasis using in vivo models of hormone-independent breast and
prostate cancer.
Methods: Cohorts of 6 (young) and 16 (mature)-week old BALB/c nude mice were culled 1, 7 and 21 days after
received intracardiac injection of luciferase expressing human prostate (PC3) or breast cancer (MDA-MB-231) cell
lines labelled with a fluorescent cell membrane dye (Vybrant DiD). The presence of growing bone metastases was
determined by bioluminescence using an in vivo imaging system (IVIS) and followed by anatomical confirmation of
tumour metastatic sites post mortem, while the presence of individual fluorescently labelled tumour cells was
evaluated using two-photon microscopy ex vivo. The bone remodelling activities were compared between young
and mature naïve mice (both male and female) using micro-CT analysis, ELISA and bone histomorphometry.
Results: Both prostate and breast cancer cells generated higher numbers of overt skeletal lesions in young mice
(~80%) than in mature mice (~20%). Although mature mice presented with fewer overt bone metastases, the
number of tumour cells arriving/colonizing in the tibias was comparable between young and mature animals.
Young naïve mice had lower bone volume but higher bone formation and resorption activities compared to
mature animals.
Conclusions: Our studies suggest that higher frequencies of growing osteolytic skeletal metastases in these models
are linked to increased bone turnover and not to the initial number of tumour cells entering the bone
microenvironment.
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Background
About 90% patients with advanced breast and prostate
cancer have incurable bone metastases [1, 2], with a
mean survival of one year [3, 4]. Treatments that aim to
either prevent or suppress the growth of bone metastasis
are limited. Anti-bone resorptive agents such as zoledro-
nic acid, prevent bone loss and skeletal-related events
(SREs), but do not increase survival in unselected pa-
tients with advanced disease [4–7]. However, a better
understanding of the early mechanisms leading to the
development of bone metastasis would allow such ther-
apies to be specifically targeted to early lesions as they
arise.
The ‘seed and soil hypothesis’ for metastasis proposes
that only the right cells disseminated from primary
tumour (the ‘seeds’) landing in the right microenviron-
ment (the ‘soil’) can form secondary (metastatic)
tumours successfully [8]. It has been suggested that
prostate and breast cancers contain a small percentage
(<1%) of stem cell-like populations and that it is these
cells that have the potential to act as the ‘seeds’, leaving
the primary site, surviving in the circulation, homing
into the bone, where they eventually form bone metasta-
ses [9–14]. In this context, bone is the fertile ‘soil’, pro-
viding a supportive microenvironment (‘bone metastasis
niche’) for tumour cell survival and secondly, under the
right conditions, for the proliferation of clinically rele-
vant metastases. New evidence has shown that dissemi-
nated prostate cancer cells target the haemopoietic stem
cell niche to establish footholds in bone, with the osteo-
blastic lineages as the key components of the niche [15,
16]. In addition, bone continuously renews itself with
precisely balanced osteoblastic bone formation and
osteoclastic bone resorption. Elevated levels of bone
turnover have been shown to be correlate with increased
numbers of metastases, in various xenograft models and
clinical studies [17–22]. Whether this effect is a result of
different bone environments increasing tumour cell
seeding, or of environments inducing proliferation of
resident tumour cells in bone to form overt metastases,
remains to be determined.
In this study, we investigated the initiation of prostate
and breast cancer bone metastases in young (6-week
old) and in mature (16-week old) athymic mice. Both
bone turnover rates and the frequency of metastases
were lower in the mature compared to the younger ani-
mals allowing us to study the initiation of metastases in
different bone microenvironments. We used two-photon
microscopy to identify initial seeding of tumour cells
into bone and compared this with the frequency of
growing metastases. This is the first study to directly test
the hypothesis that the frequency of bone metastasis is
equally dependent on numbers of seeded tumour cells
and growth induction by the bone microenvironment.
Methods
Mice
All studies were performed using 6-week or 16-week old
BALB/cAnNCrl immunocompromised (athymic nude)
mice (Charles River, Kent, UK) as xenograft models of
bone metastasis. All procedures complied with the UK
Animals (Scientific Procedures) Act 1986 and were
reviewed and approved by the local Research Ethics
Committees of the University of Sheffield under Home
Office project licence 40/3462 (Sheffield, UK).
Cell lines
The human prostate cancer cell line PC3 (ATCC,
Middlesex, UK) and human breast cancer cell line
MDA-MB-231 (ATCC, Middlesex, UK) were stably
transfected with a firefly luciferase gene luc2 (pGL4.51
[luc2/CMV/Neo] vector, Promega, Southampton, UK)
and denoted as PC3-NW1 and MDA-MB-231 luc2. Both
cell lines were maintained in Dulbecco’s Modified Eagle
Medium (DMEM) (Life Technologies, Paisley, UK),
supplemented with 100 Units/mL Penicillin, 100 μg/mL
Streptomycin and 10% foetal calf serum (FCS) (Sigma
Aldrich Co Ltd, Poole, UK).
Xenograft models
Human cancer cells were initially stained with 5 μM
lipophilic carbocyanine dye Vybrant DiD (Life Technolo-
gies, Paisley, UK) according to the manufacture’s proto-
col. Using the Vybrant DiD dye, which is lost as cells
divide, allows non-dividing/slowly dividing cells to be
identified and distinguished from proliferating cells [15,
23, 24]. A single-cell suspension of 1 × 105 DiD labelled
PC3-NW1 cells/100μL PBS and 0.75x105 DiD labelled
MDA-MB-231 luc2 cells/100μL PBS were injected into
the left cardiac ventricle (intracardiac (i.c.) injection) of
6- or 16-week old male and female BALB/c nude mice,
respectively. Overt tumours were monitored up to 8
weeks post injection using an in vivo imaging system
(IVIS, PerkinElmer, Cambridge, UK) and the tumour
burden was measured based on radiance of lumines-
cence using the Living Image software (PerkinElmer),
followed by anatomical confirmation of tumour meta-
static sites post mortem. Cohorts of animals (mini-
mum n = 6/group) were euthanized on day 1, 7 and
21 post injection and individual non-dividing DiD
labelled tumour cells were quantified in the tibiae
ex vivo by two-photon microscopy, to understand the
quantity of tumour cells arriving and colonizing within
the bone marrow.
Two-photon microscopy
Dissected right tibiae were prepared and sectioned as
described previously [15, 24]. An area of 2104 μm ×
2525 μm below the growth plate with 100 μm in depth
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was imaged using a Zeiss LSM510 NLO upright mul-
tiphoton/confocal microscope (Carl Zeiss Inl, Cam-
bridge, UK). A 633nm HeNe laser was used to detect
DiD labelled cells while the bone was detected using
the 900nm Chameleon multiphoton laser. The num-
ber of tumour cells (DiD positive events) and their
distance to the nearest bone surface (a parameter
indicating the location of tumour cells towards
osteoblastic niche) was analysed using the Volocity
3D Image Analysis software 6.01 (PerkinElmer,
Cambridge, UK).
Micro-CT analysis
Right femurs were dissected and scanned by SkyScan
1172 desktop micro-CT (SkyScan) at the resolution of 6
μm. Trabecular morphometry, characterized as trabecu-
lar bone content (BV/TV) was measured from a 1.0mm
thick region 0.2mm above the growth plate where meta-
static tumour cells are generally situated. Nomenclature
and symbols were used to describe the micro-CT de-
rived bone morphometries according to the published
guidelines [25].
Serum bone remodelling markers
Tartrate-resistant acid phosphatase 5b (TRAP) activ-
ity in mouse serum was determined as a measure of
bone resorption activity using an IDS MouseTRAP™
Assay (Immunodiagnostic Systems, Tyne & Wear,
UK). Type 1 procollagen amino-terminal-propeptide
(P1NP) and osteocalcin were determined for bone
formation activities, using a Rat/Mouse P1NP com-
petitive immunoassay kit (Immunodiagnostic Sys-
tems, Tyne & Wear, UK) and a Mouse Osteocalcin
ELISA Kits (Takara Bio Europe, Saint Germain,
France), for male and female mice samples,
respectively.
Bone histomorphometry
Dissected left tibiae were prepared and TRAP stained as
described previously [26]. The number of osteoblasts
(N.Ob/B.Pm), the bone surface covered by osteoblasts
(Ob.Pm/B.Pm), the number of osteoclasts (N.Oc/B.Pm),
and the bone surface covered by osteoclasts (Oc.Pm/
B.Pm) were determined on a 1.5mm length of endocorti-
cal surfaces, using a DMRB microscope (Leica Microsys-
tems, Wetzlar, Germany) with the Osteomeasure bone
histomorphometry software (OsteoMetrics, Inc. Decatur,
GA, USA).
Statistic analysis
All data are expressed as mean ± SEM. Statistical signifi-
cance was tested for using an unpaired Student’s t-test
using the Prism 6 software (GraphPad, La Jolla, USA).
P < 0.05 was considered to be significant.
Results
The frequency of overt, skeletal prostate cancer metastases
was elevated in young compare to mature male mice
We first established how prostate cancer cells formed
tumours in bone following intra-cardiac injection, com-
paring young and mature male mice. Three weeks after
tumour cell injection, young animals developed tumours,
observed by bioluminescence, with an overall skeletal
tumour frequency of greater than 80% in multiple exper-
iments (n = 12 in total). In contrast, only 20% of mature
animals developed skeletal tumours (n = 12) three weeks
post injection and 40% of mature animals developed
skeletal tumours by eight weeks (Fig. 1a). The young
mice had significantly higher number of skeletal tumours
(3.4 ± 0.4 tumours per mice vs 0.4 ± 0.2, p < 0.0001), but
not non-skeletal tumours in soft tissue and organs, such
as in skeletal muscle, liver, adrenal glands, except
peri- or intra-cardial tumours caused by incorrect in-
jections, compared to mature mice (0.4 ± 0.2 vs 0.3 ± 0.1,
p = 0.7314)(Fig. 1b and c). This was reflected by the total
tumour burden determined by the radiance of tumour lu-
minescence [37556 ± 10797 vs 2754 ± 1689 photons/
sec/cm2/steradian (p/sec/cm2/sr), p = 0.0043] (Fig. 1d).
The skeletal tumours clearly caused osteolytic bone
lesions in both young and old mice, as shown in the
3D micro-CT scanning image of a tumour bearing
femur of young mice associated with bone destruc-
tion (Fig. 1e). This was confirmed by significant de-
crease in trabecular bone content (BV/TV) compared
to non-tumour bearing femurs (13.6 ± 0.8 vs 3.0 ± 0.9,
p < 0.0001)(Fig. 1f ).
Seeding of prostate cancer cells to bone was not
increased in young mice
The higher frequency of tumours in bone could be due
to increased numbers of tumour cells seeding in the
niche in young animals. We therefore quantified the
number of DiD-labelled prostate cancer cells in the tibia
of male mice using two-photon microscopy ex vivo and
found that increased tumour cell seeding was not re-
sponsible for this higher frequency of bone metastases
observed in younger animals. DiD labelled prostate can-
cer cells were identified in tibial bone marrow of both
younger and older mice at different time points (1 day, 7
days, and 3 weeks) following intra cardiac injection
(Fig. 2a). Quantified using Volocity 3D image analysis
software, the time course of tumour cells homing to the
bone marrow showed a very similar pattern in younger
and older mice, with the number of resident tumour
cells reaching its peak 7 days post-injection. Significantly
fewer tumour cells were present in younger mice on day
1 and at 3 weeks post-injection (Fig. 2b). Fewer cells
were also observed in younger mice on day 7 but this
failed to reach significance. Tumour cells were found
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located in close proximity (within a 50 μm range) to
bone at all time-points in both age groups, but were
found to be located significantly closer to bone in young
animals than in mature animals 1 day post-injection.
This trend continued on day 7 but was not present at 3
weeks (Fig. 2c).
Bone turnover was higher in young compared to
mature mice
As the number of tumour cells seeded into bone is un-
likely to account for the increase in overt metastases in
young animals, we explored the effects of changes in the
bone microenvironment to this process. Using naïve
Fig. 1 Comparison of skeletal metastases by human prostate cancer cells in young and mature male mice. A single-cell suspension of 1 × 105 DiD
labelled PC3-NW1 cells/100 μL PBS was injected into the left cardiac ventricle of 6-week old (Young) or 16-week old (Mature) male BALB/c nude
mice. a Tumour growth was monitored by in vivo imaging. Skeletal tumours (red circled) were identified and confirmed by further anatomical
examination post mortem up to 8 weeks post injection. b The number of skeletal tumours per mouse, c the number of non-skeletal tumour per
mouse (skeletal muscle, liver, adrenal glands, but not peri- or intra-cardial tumours), and d the total tumour burden measured by radiance of
luminescence were also compared between young and mature mice, n = 12. e A 3D bone models created using the micro-CT scan on tumour
bearing femurs in young mice shows the bone lesions caused by these tumours. f To measure the bone destruction in trabecular compartment,
trabecular bone content (BV/TV) were then quantified and compared between tumour bearing and non-tumour bearing legs of young mice,
n > 8. (** P < 0.01, ****P < 0.0001, t-test)
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mice, we carried out detailed micro-CT analysis on distal
regions of femurs and showed that the young male mice
had 18% lower BV/TV compared to mature male mice
(17.4 ± 0.9 vs 21.2 ± 1.2, p = 0.0194)(Fig. 3a and b). How-
ever, the younger mice have greater overall bone remod-
elling activities than older mice, with evidence of nearly
3 fold more bone formation (134.3 ± 17.0 vs 34.5 ± 1.7
ng/mL, p = 0.0004) and increased bone resorption activ-
ities (5.9 ± 0.5 vs 2.7 ± 0.1 U/mL, p = 0.0002), determined
via quantifying serum P1NP and TRAP concentrations,
respectively (Fig. 3c and d). This is consistent with histo-
morphometric analysis of the osteoblasts and TRAP
positive osteoclasts on the endocortical bone surface of
the tibiae (Fig. 3e). These data showed that young male
mice had increased numbers of osteoblasts (58.5 ± 0.5 vs
28.9 ± 4.4 mm−1, p = 0.0024)(Fig. 3f ), increased areas of
osteoblast covered bone surfaces (66.7 ± 1.7 vs 38.2 ± 5.8 %,
p = 0.0056) (Fig. 3g), increased numbers of osteoclasts
(1.8 ± 0.5 vs 0.8 ± 0.1 mm−1, p = 0.0127)(Fig. 3h), and
2 fold more osteoclast covered bone surfaces (4.5 ± 1.2 vs
1.5 ± 0.2 %, p = 0.0187)(Fig. 3i) than mature animals.
In order to ensure that the above results were not
unique to the prostate cancer model we repeated the
studies using breast cancer cells injected in female mice,
assessing tumour cell seeding in bone, progression of
metastases and bone turnover.
Fig. 2 Quantification of human prostate cancer cells arriving and colonizing the bone marrow of male mice. a The DiD labelled tumour
cells entering the bone microenvironment were visualized and quantified using two-photon microscopy on day 1, 7 and 21 post tumour
cells injection. Scale bar = 200μm. b The number of tumour cells per mm3 bone marrow volume and c the minimum distance from
tumour cells to the nearest bone surface was quantified and compared between 6-week old (Young) or 16-week old (Mature) mice
using the Volocity 3D Image Analysis software. n > 6, * P < 0.05, ** P < 0.01, *** P < 0.001, t-test
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Fig. 3 (See legend on next page.)
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The frequency of overt, skeletal breast cancer metastases
was elevated in young compared to mature female mice
Three weeks after injection of DiD-labelled MDA-MB-
231 human breast cancer cells, young female mice had
developed significantly higher numbers of tumours in
the skeleton (~80%) compared to mature animals
(~50% skeletal tumours at both 3 and 8 weeks post in-
jection) (Fig. 4a). The tumours caused lytic bone le-
sions in both young and mature mice, as shown in the
3D micro-CT images of tumour bearing femurs of
young mice (Fig. 4b) and led to significant decrease in
BV/TV (12.9 ± 1.2 vs 6.7 ± 1.7, p = 0.0107) (Fig. 4c).
Younger female mice carried an average of 4.8 ± 0.5
skeletal tumours compared to 0.7 ± 0.2 in older mice
(p < 0.0001)(Fig. 4d). There was no difference in non-
skeletal tumour frequency (skeletal muscle, liver, brain
but not peri- or intra-cardial tumours) between the
groups (0.4 ± 0.2 vs 0.3 ± 0.2, p = 0.9087)(Fig. 4e). The
skeletal tumour burden in younger female mice was
about 56 fold higher than that of older mice
(13470000 ± 9121000 vs 233787 ± 82546 p/sec/cm2/sr,
p = 0.2373)(Fig. 4f ).
Similar numbers of breast cancer cells were present in
bone of young and mature female mice
To investigate whether different numbers of tumour
cells seed to and colonize bone microenvironment of
young and mature female mice, DiD labelled breast can-
cer cells were identified and quantified in tibial bone
marrow at different time points (1 day, 7 days, and 3
(See figure on previous page.)
Fig. 3 Differences of bone remodelling activities between younger and older male BALB/c nude mice. a The trabecular bone content (BV/TV) was
compared between 6-week old (Young) or 16-week old (Mature) male mice using micro-CT analysis. n > 9. b The trabecular bone mass difference
can be clearly seen on the cross-section micro-CT image 250 μm below the growth plate, scale bar = 500μm. c The bone formation marker (P1NP) and
d bone resorption marker (TRAP) were also measured in mouse serum sample using ELISA kits, n > 9. e The bone resorbing osteoclasts (TRAP
staining +, marked by black arrow heads) and bone forming osteoblasts (marked by small black arrows) were viewed and quantified on
the endocortical bone surface of 6- and 16-week old mice tibiae after sectioning and TRAP staining. Scale bar = 50μm. f The number of
osteoblasts per mm endocortical bone surface (N. Ob/B.Pm), g bone surface covered by osteoblasts (Ob.Pm/B.Pm), h number of osteoclasts per mm
endocortical bone surface (N.Oc/B.Pm), and i bone surface covered by osteoclasts (Oc.Pm/B.Pm) were all compared between 6- and 16-week old mice.
n > 4, * P < 0.05, ** P < 0.01, **** P < 0.0001, t-test
Fig. 4 Comparison of skeletal metastases by human breast cancer cells in young and mature female mice. A single-cell suspension of 0.75 × 105
DiD labelled MDA-MB-231-luc2 cells/100 μL PBS was injected into the left cardiac ventricle of 6-week old (Young) or 16-week old (Mature) female
BALB/c nude mice. a Tumour growth was monitored using the in vivo imaging system (IVIS). Skeletal tumours (red circled) were identified and
confirmed by further anatomical examination post mortem up to 8 weeks post injection. b The bone lesions were examined and confirmed from
3D bone models created via micro-CT scanning tumour bearing femurs of young mice. c BV/TV was then quantified and compared between
tumour bearing and non-tumour bearing legs of young mice, n = 4. d The number of skeletal tumours per mouse, e the number of non-skeletal
tumour per mouse (skeletal muscle, liver, adrenal glands, but not peri- or intra-cardial tumours), and f the total tumour burden (radiance of
luminescence) were also compared between 6- and 16-week old mice, n > 6. (* P < 0.05, ****P < 0.0001, t-test)
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weeks post injection) using two-photon microscopy ex
vivo (Fig. 5a). There were no significant differences be-
tween young and mature mice at 1 and 7 days post in-
ject, while significantly fewer tumour cells were found in
young animals 3 weeks post injection (Fig. 5b). There
was also no difference between younger and older fe-
male mice in the distances from tumour cells to the
nearest bone surfaces (Fig. 5c).
Bone turnover was higher in young compared to mature
female mice
To evaluate differences in bone remodelling activities,
detailed analyses of bone structure were performed and
phenotypes were compared between the young and
mature female mice. Micro-CT analysis on femurs
showed that the young female mice had 18% less
BT/TV compared to mature animals (7.7 ± 0.5 vs
12.2 ± 0.6, p = 0.0007)(Fig. 6a and b). The young mice
had evidence of higher bone formation (98.0 ± 3.2 vs
36.7 ± 6.7 ng/mL osteocalcin in serum samples, p <
0.0001)(Fig. 6c) and 4 fold greater bone resorption
activity (22.2 ± 0.3 vs 4.4 ± 0.3 U/mL TRAP activity,
p < 0.0001) than the mature mice (Fig. 6d). Quanti-
fied at cellular level and compared to mature mice,
younger female mice have 136% more osteoblasts
(74.4 ± 5.8 vs 31.5 ± 7.6 mm−1, p = 0.0007)(Fig. 6e)
and 89% more osteoblast covered bone surfaces
(72.1 ± 4.3 vs 38.2 ± 8.8 %, p = 0.0028)(Fig. 6f ). In
Fig. 5 Quantification of human breast cancer cells arriving and colonizing the bone marrow of female mice. a The DiD labelled tumour cells
entering the bone microenvironment were visualized and quantified using a two-photon microscopy on day 1, 7 and 21 post tumour injection.
Scale bar = 200μm. b The number of tumour cells per mm3 bone marrow volume and c the minimum distance from tumour cells to bone
surfaces were quantified and compared between 6- and 16-week old mice using the Volocity 3D Image Analysis software. n > 6, ** P < 0.01, t-test
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terms of osteoclasts, the young mice have 334% more os-
teoclasts (2.0 ± 0.2 vs 0.5 ± 0.2 mm−1, p = 0.0002)(Fig. 6g)
and 389% more osteoclast covered bone surfaces (5.6 ± 0.9
vs 1.2 ± 0.4 %, p = 0.0018)(Fig. 6h).
Discussion
The ‘Seeds and soils’ hypothesis suggests that both the
metastasis initiating tumour cells and the microenviron-
ment are equally important for the initiation of
Fig. 6 Differences of bone remodelling activities between young and mature female BALB/c nude mice. a & b BV/TV was compared between
6-week old (Young) or 16-week old (Mature) female mice using the micro-CT analysis. n > 6, scale bar = 500μm. c The bone formation marker
(Osteocalcin) and d bone resorption marker (TRAP) were also measured in mouse serum sample by ELISA, n = 5. e The number of osteoblasts per
mm endocortical bone surface (N. Ob/B.Pm), f bone surface covered by osteoblasts (Ob.Pm/B.Pm), g number of osteoclasts per mm endocortical
bone surface (N.Oc/B.Pm), and h bone surface covered by osteoclasts (Oc.Pm/B.Pm) were all compared between young and mature mice. n > 4,
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, t-test
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metastases [8]. To test this, we used different aged (6-
week and 16-week old) immunocompromised mice as
xenograft models to investigate the relationship between
numbers of tumour cells colonizing bone, bone turnover,
and the incidence of osteolytic skeletal metastases
caused by prostate and breast cancer.
In the prostate cancer model, bioluminescent signals
were clearly visible in the skeleton, three weeks after ini-
tial tumour cell injection. As bioluminescence detects
bone marrow metastases of ≈ 0.5mm3 volume [27], the
signals detected were indicative of overt, growing le-
sions. These lesions were associated with bone destruc-
tion that was confirmed by anatomical confirmation and
micro-CT analysis post mortem. The results showed that
both the frequency of skeletal metastases and tumour
burden were higher in young mice compare to mature
mice. However, there were no differences in the inci-
dence of metastases in soft tissues. This indicates that
the difference in the frequency of metastases across dif-
ferent aged cohorts is unique to the skeletal system and
determined by the bone microenvironment. Further
examination of the bone phenotype showed that young
male mice had lower bone mass compared to mature
animals but higher bone turnover. This was charac-
terised by significant increases in the numbers of osteo-
blasts and osteoclasts, and elevated bone formation and
resorption activities. This is consistent with clinical stud-
ies which suggested higher levels of bone turnover pre-
dict poor outcome in patients with bone metastasis [20,
22, 28]. To determine whether the higher metastasis fre-
quency is due to higher numbers of metastasis initiating
cells taking up residency in bone, we quantified the
numbers of prostate cancer cells present in the bone
marrow across a three-week period after initial injec-
tion, using two-photon microscopy and cell membrane
labelling techniques. The results suggested that there were
no increase in prostate cancer cells arriving in the bone
marrow of young mice compared to mature animals and
that these cells were in direct contact or one cell layer
away from bone surface osteoblast lineage cells as they
were within a range of 50 μm to the nearest bone surface
on which an osteoblast has a typical diameter of 15-30 μm
[29]. Surprisingly, there were significantly more tumour
cells detected in the bone marrow of mature mice on day
1 and at 3 weeks post injection. This warrants further in-
vestigation. One explanation is that fewer DiD labelled
tumour cells were detected in younger mice as a result of
more proliferation and consequent loss of dye [24]. An-
other possibility is that the low bone turnover micro-
environment in mature mice is more selective for stem
cell-like cancer cells, while high bone turnover micro-
environment in younger mice are more supportive to the
growth of metastases and may correlated with angiogen-
esis which will be discussed in following sections. These
data suggest that the higher frequency of skeletal metasta-
ses for prostate cancer in younger xenograft models is not
due to increased tumour cells homing to the bone marrow
but supports the hypothesis that it is the bone microenvir-
onment that controls the frequency of growing metastases
detected in these xenograft models, through induction of
lesion initiation and growth [30, 31].
Similar results were found in the breast cancer model.
Significantly higher frequencies and levels of tumour
burden, determined by bioluminescence and anatomical
confirmation post-mortem, were found in young female
mice compared to mature mice. This was not due to
higher number of breast cancer cells arriving into the
bone marrow of younger animals, but correlated with
the enhanced bone turnover activities confirmed by both
ELISA of serum bone turnover marker (osteocalcin and
TRAP) and histomorphometric analysis of osteoblasts
and osteoclasts. Once again, there was a trend towards
more tumour cells being detected in bone marrow of
older female mice.
Taken together, the differences in frequency of skeletal
metastases between young and mature mice in both
prostate and breast cancer models strongly suggested
that it is the trigger for the proliferation of resident
tumour cells in bone that is linked to the differences in
bone turnover in the bone microenvironment. This is
consistent with previous findings of our own and of
others that showed increased frequencies of bone metas-
tases by prostate and breast cancer xenograft models in
mature animals with experimentally induced enhance-
ment of bone turnover [17, 18, 32]. More importantly,
these data correlate with disease outcomes in cancer pa-
tients: Breast cancer patients presenting at a younger
age (<40) have worse survival rates and more metastases
compared to disease presented in older women, while
younger men (<44) with high grade prostate cancer, have
poorer prognosis compared to older men with a similar
grade/stage distribution [33, 34]. One could argue these
differences are due to higher available sex steroid hor-
mone levels rather than the higher bone turnover in
younger populations, directly affecting tumour growth.
However, our data suggests another mechanism, as we
intentionally used sex steroid hormone-independent cell
lines: PC3 and MDA-MB-231 in these studies that are
unaffected by androgens/oestrogens.
The xenograft model used in this study has limitations:
firstly, we could not determine the role of the immune
system, specifically T cells, in regulating metastatic fre-
quency. The latter have been implicated in the bone
metastatic process [35]. Secondly, the administration of
a single high dose of cancer cells via intracardiac injec-
tion only partially mirrors seeding events in humans
where low numbers of cancer cells are released into the
circulation over prolonged time intervals. Finally, other
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differences between young and mature mice could also
contribute to variations in metastatic frequencies such
as the higher growth hormone levels and continuous
longitudinal bone growth in younger mice. Particularly,
differences in endothelial lineage populations and associ-
ated niches could also affect metastasis frequency and
should be investigated [16]. Tumour cells were shown
to be rapidly engrafted into bone marrow endothelial
microdomains, where endothelial cells express higher
level of adhesion molecules such as E-selectin, P-
selectin, and intercellular adhesion molecule (ICAM-1)
[36–38]. Kusumbe et al. recently showed that there are
two distinct bone microvessels based on the expression
of CD31 (also known as PECAM1) and Endomucin
(Emcn), which were proposed as type H subset
(CD31hiEmcnhi) and type L subset (CD31loEmcnlo) [39].
The type H subset expresses higher level of metastasis
related growth factor transcripts such as Tgfb1 and
Tgfb3 [40]. The type H subset is a key to couple angio-
genesis to osteogenesis and was strongly reduced in
bone from aged animals [39]. This study suggested that
the correlation of higher incidence of skeletal tumours
in younger animals with the presence of type H micro-
vessels in addition to higher bone turnover.
In conclusion, our study using two established meta-
static cancer cell lines, provides further evidence to sup-
port the hypothesis that the frequency of overt skeletal
metastases in hormone-independent prostate and breast
cancer is determined by growth initiating influences
within the bone microenvironment not by numbers of
tumour cell initially seeding to these sites and provides
further grounds for the use of treatments to suppress
bone turnover and prevent development of skeletal me-
tastases of prostate and breast cancer at early stages of
disease.
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